A Clinical Study of HH-1270 in Healthy Chinese Subjects

November 17, 2026 updated by: Huahui Health

A Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetic Characteristics of HH-1270 Tablets in Healthy Chinese Participants

This study is a single-center, randomized, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) clinical trial to evaluate the safety and PK profile in healthy Chinese subjects.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Detailed Description

SAD consists of 6 prespecified dose levels. Participants are enrolled in cohorts according to the dose-escalation principle and randomized to receive HH-1270 tablets (A) or placebo (P). Higher dose cohorts may begin only after confirmation by the SRC for the lower dose cohort. This part aims to evaluate the safety, tolerability, PK, and PD characteristics of single-dose HH-1270. One dose cohort in the SAD phase will be selected for a food-effect exploration.

MAD consists of 4 prespecified dose levels. Each participant receives once-daily dosing under fasting conditions for 7 consecutive days and is randomized to receive HH-1270 tablets (A) or placebo (P). Higher dose cohorts may begin only after confirmation by the SRC for the lower dose cohort. This part aims to evaluate the safety, tolerability, PK, and PD characteristics of multiple-dose HH-1270.

Study Type

Interventional

Enrollment (Estimated)

88

Phase

  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Beijing Municipality
      • Beijing, Beijing Municipality, China, 100191
        • Recruiting
        • Peking University Third Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 55 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Healthy Chinese adults aged 18 to 55 years (inclusive), both male and female.
  • Weight: male ≥50.0 kg, female ≥45.0 kg, and body mass index (BMI) 18.0 to 28.0 kg/m² (inclusive; BMI = weight/height²).
  • Results of vital signs, physical examination, laboratory tests, and 12-lead electrocardiogram (ECG) at screening are normal or abnormal without clinical significance.
  • Participants must agree to take adequate and effective contraceptive measures.
  • Participants understand and comply with the study procedures, voluntarily participate, and sign the informed consent form (ICF).

Exclusion Criteria:

  • Individuals with severe systemic diseases, infectious diseases, or mental disorders.
  • Clinically significant electrocardiogram (ECG) abnormalities.
  • History of clinically significant drug allergy or atopic allergic diseases.
  • Comorbid conditions that may affect drug absorption, distribution, metabolism, excretion, and interpretation of safety data, or that may reduce compliance, including but not limited to any of the following.
  • Positive results for human immunodeficiency virus (HIV) antibody, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibody, or Treponema pallidum antibody (TPAb).
  • History of drug abuse or alcoholism within 12 months before screening, or evidence of alcohol abuse or excessive drinking confirmed by an alcohol breath test at screening.
  • Frequent use of tobacco or nicotine products (e.g., patches, gum, etc.) or any other smoking products within 30 days before screening.
  • Blood donation ≥400 mL within 3 months before screening.
  • Participation in another interventional clinical trial within 3 months before screening.
  • Use of any prescription medication within 4 weeks or 5 half-lives (whichever is longer) before screening.
  • Use of over-the-counter drugs, health supplements, herbal medicines, or traditional Chinese medicines, or use of medications that affect drug metabolism, within 2 weeks before screening.
  • Known or suspected history of allergy to any component of HH-1270 tablets or their excipients.
  • Inability to accept standardized diet management at the study center.
  • Participants who are breastfeeding or have a positive pregnancy test before the first dose.
  • Participants deemed unsuitable for participation in the study by the investigator.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: HH-1270 group

SAD groups will be received HH-1270 tablets from 5mg to 200mg once and MAD groups will be received HH-1270 tablets from 5 mg to 60 mg once per day for 7 days

SAD groups will be received HH-1270 tablets from 5mg to 200mg once and MAD groups will be received HH-1270 tablets from 5 mg to 60 mg once per day for 7 days

Placebo Comparator: Placebo group

SAD groups will be received HH-1270 placebo tablets from 5mg to 200mg once and MAD groups will be received HH-1270 placebo tablets from 5 mg to 60 mg once per day for 7 days

SAD groups will be received placebo tablets from 5mg to 200mg once and MAD groups will be received HH-1270 placebo tablets from 5 mg to 60 mg once per day for 7 days

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Incidence of adverse events (AEs) and serious adverse events (SAEs)
Time Frame: up to 15/21 days in SAD/MAD

Number of subjects with adverse events (AEs) and serious adverse events (SAEs) assessed by the Common Terminology Criteria for Adverse Events (CTCAE) v6.0.

up to 15/21 days in SAD/MAD
Clinically significant abnormalities
Time Frame: up to 14/21 days in SAD/MAD

Number of subjects with clinically significant abnormalities in vital signs, electrocardiogram (ECG), and laboratory parameters graded by CTCAE v6.0.

up to 14/21 days in SAD/MAD

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Area Under the Plasma Concentration Versus Time Curve (AUC)
Time Frame: up to 8/14 days in SAD/MAD

AUC of HH-1270 in plasma

up to 8/14 days in SAD/MAD
Maximum Plasma Concentration (Cmax)
Time Frame: up to 8/14 days in SAD/MAD

Cmax of HH-1270 in plasma

up to 8/14 days in SAD/MAD
Time to Reach Maximum Plasma Concentration (Tmax)
Time Frame: up to 8/14 days in SAD/MAD

Tmax of HH-1270 in plasma

up to 8/14 days in SAD/MAD
Apparent Terminal Elimination Half-life (T1/2)
Time Frame: up to 8/14 days in SAD/MAD

T1/2 of HH-1270 in plasma

up to 8/14 days in SAD/MAD
Apparent Plasma Clearance (CL/F)
Time Frame: up to 8/14 days in SAD/MAD

CL/F of HH-1270 in plasma

up to 8/14 days in SAD/MAD
Apparent volume of distribution(Vd/F)
Time Frame: up to 8/14 days in SAD/MAD

Vd/F of HH-1270 in plasma

up to 8/14 days in SAD/MAD
To evaluate the TBA level
Time Frame: up to 15/21 days in SAD/MAD

TBA level for each collection point

up to 15/21 days in SAD/MAD
To evaluate the CP-1 level
Time Frame: up to 15/21 days in SAD/MAD

CP-1 level for each collection point

up to 15/21 days in SAD/MAD

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
To evaluate QTc change
Time Frame: up to 8 days in SAD

QTc values in each collection point

up to 8 days in SAD

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

October 19, 2026

Primary Completion (Estimated)

February 5, 2027

Study Completion (Estimated)

July 6, 2027

Study Registration Dates

First Submitted

October 9, 2026

First Submitted That Met QC Criteria

October 9, 2026

First Posted (Actual)

October 15, 2026

Study Record Updates

Last Update Posted (Actual)

November 18, 2026

Last Update Submitted That Met QC Criteria

November 17, 2026

Last Verified

November 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • HH1270-101

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.